NBIXHealthcare · Drug Manufacturers - Specialty & GenericThe 27 Wall Street analysts covering Neurocrine Biosciences, Inc. hold a median 12-month price target of $215 — +40.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Neurocrine Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (30): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NBIX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +40.8% from it.
Of the 20 most recent actions, 10 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Morgan Stanley | Maintains | Equal-Weight | $196 → $182 |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Buy | $200 → $210 |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 3 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 3 Aug 2026 | Truist Securities | Maintains | Buy | $200 → $213 |
| 3 Aug 2026 | Wedbush | Maintains | Outperform | $185 → $194 |
| 3 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 31 July 2026 | Cantor Fitzgerald | Maintains | Overweight | $210 → $215 |
| 31 July 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 31 July 2026 | Citigroup | Maintains | Buy | — |
| 31 July 2026 | Citigroup | Maintains | Buy | $246 → $249 |
| 31 July 2026 | Guggenheim | Maintains | Buy | $200 → $222 |
| 31 July 2026 | Guggenheim | Maintains | Buy | — |
| 31 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 31 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $193 → $196 |
| 31 July 2026 | Needham | Maintains | Buy | $200 → $204 |
| 31 July 2026 | Needham | Maintains | Buy | — |
| 31 July 2026 | Piper Sandler | Maintains | Overweight | — |
| 31 July 2026 | Piper Sandler | Maintains | Overweight | $207 → $210 |
| 31 July 2026 | RBC Capital | Maintains | Outperform | $195 → $198 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NBIX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 35% of US stocks
Cheaper than 28% of US stocks
Cheaper than 26% of US stocks
Cheaper than 20% of US stocks
Higher than 83% of US stocks
Higher than 69% of US stocks
Higher than 99% of US stocks
Higher than 81% of US stocks
Higher than 83% of US stocks
Higher than 83% of US stocks
Higher than 94% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Neurocrine Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Neurocrine Biosciences stock fell nearly 5% on Wednesday before recovering after physicians and Prader-Willi syndrome experts alerted clinicians to cases of deaths and severe complications potentially linked to Vykat XR (diazoxide choline).
Why it matters — Safety concerns surrounding Vykat XR, a Neurocrine product, could affect investor perception of the drug's risk profile.
Neurocrine Biosciences announced the publication of KINECT-PRO study results showing that INGREZZA (valbenazine) improved patient-reported quality of life and daily functioning in people with tardive dyskinesia, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severity.
Why it matters — The publication provides clinical evidence that INGREZZA improves quality of life and functionality in tardive dyskinesia patients, reinforcing the drug's value proposition for Neurocrine's key product.
Experts in Prader-Willi Syndrome raised safety concerns about Neurocrine's drug Vykat XR, citing serious adverse events reported in patients with the rare genetic disorder. The concerns were voiced on Tuesday, according to Reuters.
Why it matters — Safety concerns over Vykat XR could affect the regulatory and commercial outlook for one of Neurocrine's rare disease products, a key focus for NBIX watchers.
Neurocrine Biosciences announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. The company described the milestone as advancing its obesity portfolio and metabolic disease pipeline.
Why it matters — This marks the company's entry of its investigational obesity candidate into human trials, advancing its metabolic disease pipeline with potential new treatment options for a chronic disease.
Neurocrine Biosciences reported its Q2 2025 earnings, highlighting portfolio expansion driven by growth of INGREZZA, CRENESSITY and VYKAT XR, as well as progress in pipeline catalysts and commercial momentum.
Why it matters — The update showcases broadening commercial and pipeline prospects beyond Neurocrine's flagship drug INGREZZA, which could signal a more diversified revenue base for the company.
The 27 Wall Street analysts covering Neurocrine Biosciences, Inc. have a median 12-month price target of $215, with estimates ranging from $165 to $249. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering Neurocrine Biosciences, Inc., 23 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurocrine Biosciences, Inc. 89 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Neurocrine Biosciences, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies +40.8% from the last close, and Ticker Nerd's factor model ranks Neurocrine Biosciences, Inc. 89 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Neurocrine Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NBIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $165 to $249 over the next 12 months.
Neurocrine Biosciences, Inc. returned +16.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company headquartered in San Diego, California.
The most recent item we track (Benzinga, 12 Aug 2026): "What's Going On With Neurocrine Biosciences Stock On Wednesday?". Neurocrine Biosciences stock fell nearly 5% on Wednesday before recovering after physicians and Prader-Willi syndrome experts alerted clinicians to cases of deaths and severe complications potentially linked to Vykat XR (diazoxide choline).
Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company headquartered in San Diego, California. The company specializes in discovering, developing, and commercializing medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its marketed portfolio addresses a range of conditions, including tardive dyskinesia and chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, adrenal insufficiency, endometriosis, and uterine fibroids. Key products include INGREZZA for movement disorders, ALKINDI and Efmody for adrenal-related conditions, Orilissa and Oriahnn for gynecologic disorders, and CRENESSITY for congenital adrenal hyperplasia. Following the acquisition of Soleno Therapeutics, Neurocrine Biosciences also offers VYKAT XR, a therapy targeting hyperphagia in Prader-Willi syndrome, expanding its presence in rare endocrine and metabolic diseases. The company serves patients and healthcare providers in the United States and internationally, playing a significant role in specialty pharmaceuticals for complex central nervous system and endocrine conditions. Founded in 1992, it operates today as a key player in the biopharmaceutical segment of the healthcare market.
CEO Mr. Kyle W. Gano Ph.D. · 2,500 employees · United States · https://www.neurocrine.com